Abstract
Patients with widely differing degrees of cardiovascular risk can derive benefit from effective lipid-lowering therapy with statins, including patients with normal or low cholesterol levels. Clinical trials with fluvastatin have shown that it is effective in patients across a broad spectrum of cardiovascular risk. The lipid-lowering effects of fluvastatin are smaller than some statins, but major clinical outcome studies have consistently demonstrated morbidity and mortality benefits with reductions of low-density lipoprotein cholesterol of
Original language | English |
---|---|
Pages (from-to) | 494-503 |
Number of pages | 10 |
Journal | International Journal of Clinical Practice |
Volume | 58 |
Issue number | 5 |
DOIs | |
Publication status | Published - May 2004 |
Keywords
- Adverse effects
- Cardiovascular benefits
- Drug interactions
- HMG-CoA reductase inhibitors
- Hypercholesterolaemia
- Pleiotropic effects
ASJC Scopus subject areas
- Medicine(all)